Volume 10, Issue 4

Pulmonary Exacerbations and IV Antibiotics

In this issue:

Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care?  

Join us for this eCysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explains how these questions can affect clinical care. 

Learning objectives:

  • Discuss the impact of prolonged treatments with intravenous antibiotics for pulmonary exacerbations. 
  • Describe some of the limitations of the evidence for treating pulmonary exacerbations in clinical practice. 

Author:

D.B. Sanders, MD, MS
D.B. Sanders, MD, MS

Associate Professor of Pediatrics
Department of Pediatrics
Indiana University School of Medicine
Cystic Fibrosis Center Director
Division of Pediatric Pulmonology, Allergy and Sleep Medicine
Riley Hospital for Children

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Donna Peeler, RN

Clinical Nurse 
Pediatric Clinic Coordinator 
Johns Hopkins Cystic Fibrosis Center 
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: July 19, 2022
Expiration date: July 18, 2024